AMPE - Ampio Pharmaceuticals Inc.

AMPE Stock Chart

AMPE Profile

Ampio Pharmaceuticals, Inc. is a biofarmaceutical company that focuses on developing immunomodulatory therapies for pain management, particularly for osteoarthritis, in the United States. Its leading product, AP-013, is an intra-articular injection currently in Phase III clinical trials for treating osteoarthritis of the knee.

The company also has several other products in its pipeline targeting COVID-19. These include AP-017, an intravenous Ampion treatment in Phase II trials for adult COVID-19 patients needing oxygen supplementation, AP-019, an inhaled Ampion treatment in Phase II trials for adults with respiratory distress due to COVID-19, and AP-018, which is in Phase I trials for patients with prolonged respiratory symptoms following COVID-19.

Founded and headquartered in Englewood, Colorado, Ampio Pharmaceuticals is dedicated to advancing its research and development efforts to bring effective treatments to market. By focusing on both osteoarthritis and COVID-19 related therapies, the company aims to address significant unmet medical needs and improve patient outcomes.

AMPE Revenue Chart

AMPE Earnings

Analyst Ratings